Table 3 Primary and secondary outcomes
Primary outcome, 28-day survival in the Low-NED (≤ 0.25 µg/kg/min) subgroup | |||
|---|---|---|---|
Placebo (n = 48) | AT II (n = 56) | HR (95% CI) | p-value |
48% (33%–61%) | 64% (50%–75%) | 0.51 (0.27, 0.95) | 0.03 |
Secondary outcome, 28-day survival in the High-NED (> 0.25 µg/kg/min) subgroup | |||
|---|---|---|---|
Placebo (n = 110) | AT II (n = 107) | HR (95% CI) | p-value |
45% (36–54%) | 49% (39–58%) | 0.93 (0.64, 1.35) | 0.71 |